Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-LNC1010 in SSTR2-positive Tumors
NCT05410743Phase 2Completed
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Jun 2022
- Primary completion
- Mar 2025
- Modality
- RT (Radiotherapy), Targeted therapy
- Countries
- 1
01
Overview
Phase 2, open-label trial of 177Lu-LNC1010 in Neuroendocrine Neoplasm (NEN) (4 arms), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoints: Incidence of treatment-related adverse events and Efficacy. Started Jun 2022; status: completed.
02
Drugs
177Lu-LNC1010
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT05410743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05410743.